AIDS and Behavior

, Volume 21, Issue 4, pp 1129–1137 | Cite as

Erectile Dysfunction Medication Prescription and Condomless Intercourse in HIV-Infected Men Who have Sex with Men in the United States

  • Xia Lin
  • Christine L. Mattson
  • Mark Freedman
  • Jacek Skarbinski
  • For the Medical Monitoring Project
Original Paper
First Online:

Abstract

Using nationally representative data, we assessed the prevalence of erectile dysfunction medication (EDM) prescription, and its association with insertive condomless anal intercourse (CAI) with an HIV-serodiscordant partner among sexually-active HIV-infected men who have sex with men (MSM) receiving medical care in the United States. Overall, 14 % (95 % CI 12–16) were prescribed EDM and 21 % (95 % CI 19–23) engaged in serodiscordant CAI. MSM who were prescribed EDM were more likely to engage in insertive CAI with a serodiscordant casual partner than those not prescribed EDM after adjusting for illicit drug use before or during sex (adjusted prevalence ratio = 1.38; 95 % CI 1.01–1.88). We found no association with main partners. Only 40 % (95 % CI 36–44) of MSM prescribed EDM received risk-reduction counseling from healthcare professionals. Risk-reduction counseling should be provided at least annually to all HIV-infected persons as recommended, especially at the time of EDM prescription.

Keywords

Erectile dysfunction medication HIV-infected persons Men who have sex with men Condomless anal intercourse 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors thank the MMP patients, facilities and Community and Provider Advisory Board members. They also thank the MMP staff (2009–2012): http://www.cdc.gov/hiv/pdf/research_mmp_studygroupmembers_2009.pdf; http://www.cdc.gov/hiv/pdf/research_mmp_studygroupmembers_2010.pdf; http://www.cdc.gov/hiv/pdf/research_mmp_studygroupmembers_2011.pdf; http://www.cdc.gov/hiv/pdf/research_mmp_studygroupmembers_2012.pdf.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.

Compliance with ethical standards

The Medical Monitoring Project (MMP) is funded by the Centers for Disease Control and Prevention. All authors declare no conflicts of interest. The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention determined that MMP was a public health surveillance activity and not subject to federal institutional review board review. However, some jurisdictions obtained approval from local Institutional Review Boards. All participants provided informed consent to participate in the interview.

References

  1. 1.
    Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012;17(No. 4). http://www.cdc.gov/hiv/library/reports/surveillance. Published December 2012. Accessed January 2016.
  2. 2.
    Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8:e81355.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Aging and HIV Infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Buchacz K, Baker RK, Palella FJ Jr, Shaw L, Patel P, Lichtenstein KA, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013;18(1):65–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. J Acquir Immune Defic Syndr. 2002;30:187–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS. 2004;15:732–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS. 2007;21:9–19.CrossRefPubMedGoogle Scholar
  8. 8.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.PubMedGoogle Scholar
  9. 9.
    Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120:151–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Foster SA, Annunziata K, Shortridge EF, Freedman D, Viktrup L. Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness Survey. Curr Med Res Opin. 2013;29:1709–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Asboe D, Catalan J, Mandalia S, Dedes N, Florence E, Schrooten W, et al. Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors. AIDS Care. 2007;19:955–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men. Int J STD AIDS. 2004;15:234–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Ende AR, Lo Re V 3rd, DiNubile MJ, Mounzer K. Erectile dysfunction in an urban HIV-positive population. AIDS Patient Care STDS. 2006;20:75–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Perez I, Moreno T, Navarro F, Santos J, Palacios R. Prevalence and factors associated with erectile dysfunction in a cohort of HIV-infected patients. Int J STD AIDS. 2013;24:712–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Santi D, Brigante G, Zona S, Guaraldi G, Rochira V. Male sexual dysfunction and HIV—a clinical perspective. Nat Rev Urol. 2014;11:99–109.CrossRefPubMedGoogle Scholar
  16. 16.
    Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS. 2005;19:655–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Colson AE, Keller MJ, Sax PE, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:27–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Shaeer O. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. J Sex Med. 2013;10:532–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Pantalone DW, Bimbi DS, Parsons JT. Motivations for the recreational use of erectile enhancing medications in urban gay and bisexual men. Sex Transm Infect. 2008;84:458–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Mansergh G, Shouse RL, Marks G, Guzman R, Rader M, Buchbinder S, et al. Methamphetamine and sildenafil (Viagra) use are linked to unprotected receptive and insertive anal sex, respectively, in a sample of men who have sex with men. Sex Transm Infect. 2006;2:131–4.CrossRefGoogle Scholar
  21. 21.
    Nettles CD, Benotsch EG, Uban KA. Sexual risk behaviors among men who have sex with men using erectile dysfunction medications. AIDS Patient Care STDS. 2009;23:1017–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Hirshfield S, Remien RH, Humberstone M, Walavalkar I, Chiasson MA. Substance use and high-risk sex among men who have sex with men: a national online study in the USA. AIDS Care. 2004;16:1036–47.CrossRefPubMedGoogle Scholar
  23. 23.
    Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28:1509–19.CrossRefPubMedGoogle Scholar
  24. 24.
    Woolf-King SE, Rice TM, Truong HM, Woods WJ, Jerome RC, Carrico AW. Substance use and HIV risk behavior among men who have sex with men: the role of sexual compulsivity. J Urban Health. 2013;90:948–52.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Spindler HH, Scheer S, Chen SY, Klausner JD, Katz MH, Valleroy LA, et al. Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco. Sex Transm Dis. 2007;34:586–91.PubMedGoogle Scholar
  26. 26.
    Ostrow DG, Plankey MW, Cox C, Li X, Shoptaw S, Jacobson LP, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr. 2009;51:349–55.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Prestage G, Jin F, Kippax S, Zablotska I, Imrie J, Grulich A. Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. J Sex Med. 2009;6:2311–20.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim AA, Kent CK, Klausner JD. Increased risk of HIV and sexually transmitted disease transmission among gay or bisexual men who use Viagra, San Francisco 2000–2001. AIDS. 2002;16:1425–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Frankel MR, McNaghten A, Shapiro MF, Sullivan PS, Berry SH, Johnson CH, et al. A probability sample for monitoring the HIV-infected population in care in the U.S. and in selected states. Open AIDS J 2012; 6:67–76.Google Scholar
  30. 30.
    Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection—Medical Monitoring Project, United States, 2009. MMWR Surveill Summ. 2014;63(Suppl 5):1–22.Google Scholar
  31. 31.
    Centers for Disease Control and Prevention. Behavioral and Clinical Characteristics of Persons Receiving Medical Care for HIV Infection—Medical Monitoring Project, United States, 2010. HIV Surveillance Special Report 9. http://www.cdc.gov/hiv/library/reports/surveillance/#special. Published October 2014. Accessed January 2016.
  32. 32.
    Centers for Disease Control and Prevention. Behavioral and Clinical Characteristics of Persons Receiving Medical Care for HIV Infection—Medical Monitoring Project, United States, 2011. HIV Surveillance Special Report 10. http://www.cdc.gov/hiv/library/reports/surveillance/#special. Published January 2015. Accessed January 2016.
  33. 33.
    Heeringa SG, West BT, Berglund PA. Applied survey data analysis. London: Chapman and Hall; 2010.CrossRefGoogle Scholar
  34. 34.
    Sarndal C-E, Lundstrom S. Estimation in surveys with non-response. Chichester: Wiley; 2005.CrossRefGoogle Scholar
  35. 35.
    Centers for Disease Control and Prevention. Distinguishing public health research and public health nonresearch. http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf. Published in 2010. Accessed January 2016.
  36. 36.
    Protection of Human Subjects. US Federal Code Title 45 Part 46. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html. Published in 2009. Accessed January 2016.
  37. 37.
    Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163–73.CrossRefPubMedGoogle Scholar
  38. 38.
    SAS Institute Inc. Base SAS 9.3 utilities; reference. Cary, NC: SAS Institute Inc; 2011.Google Scholar
  39. 39.
    SUDAAN 10.0.1. Research Triangle Park, NC: RTI International; 2009.Google Scholar
  40. 40.
    Purcell DW, Wolitski RJ, Hoff CC, Parsons JT, Woods WJ, Halkitis PN. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. AIDS. 2005;19(Suppl 1):S57–66.CrossRefPubMedGoogle Scholar
  41. 41.
    Chu PL, McFarland W, Gibson S, Weide D, Henne J, Miller P, et al. Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr. 2003;33:191–3.CrossRefPubMedGoogle Scholar
  42. 42.
    Swearingen SG, Klausner JD. Sildenafil use, sexual risk behavior, and risk for sexually transmitted diseases, including HIV infection. Am J Med. 2005;118:571–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Moreau-Gruet F, Jeannin A, Dubois-Arber F, Spencer B. Management of the risk of HIV infection in male homosexual couples. AIDS. 2001;15(8):1025–35.CrossRefPubMedGoogle Scholar
  44. 44.
    McLean J, Boulton M, Brookes M, Lakhani D, Fitzpatrick R, Dawson J, et al. Regular partners and risky behaviour: why do gay men have unprotected intercourse? AIDS Care. 1994;6(3):331–41.CrossRefPubMedGoogle Scholar
  45. 45.
    Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS. 2009;23(9):1153–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Gardner LI, Marks G, O’Daniels CM, Wilson TE, Golin C, Wright J, et al. Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS. 2008;22:627–35.CrossRefPubMedGoogle Scholar
  48. 48.
    Centers for Disease Control and Prevention, the Health Resources and Services Administration, the National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014; http://stacks.cdc.gov/view/cdc/26062. Published in 2014. Accessed January 2016.
  49. 49.
    Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, and Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. http://stacks.cdc.gov/view/cdc/26063. Published in 2014. Accessed January 2016.
  50. 50.
    Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014 Clinical Practice Guideline. http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Published in 2014. Accessed January 2016.

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  • Xia Lin
    • 1
    • 2
  • Christine L. Mattson
    • 2
  • Mark Freedman
    • 2
  • Jacek Skarbinski
    • 2
  • For the Medical Monitoring Project
  1. 1.Epidemic Intelligence ServiceCenters for Disease Control and Prevention (CDC)AtlantaUSA
  2. 2.Division of HIV/AIDS PreventionNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDCAtlantaUSA

Personalised recommendations